← Leaderboards
John P. Leonard
Weill Medical College Of Cornell Univ
$596,754
Attributed
$596,754
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$596,754 · 3
By mechanism
K23$540,000 · 1
M01$56,754 · 2
Top collaborators
No co-investigators on record.
Most similar at Weill Medical College Of Cornell Univ
Same institution · by research overlap
- Christopher D Lima$21,002,923
- Steven S Gross$23,127,784
- David J Christini$15,522,093
- Hugh C Hemmings$11,946,316
- Robert W. Grady$4,332,176
Others in their field
Top investigators on “Neoplasm /Cancer Chemotherapy”
- Charles A Coltman · Southwest Oncology Group$171,655,324
- Norman Wolmark · Nsabp Foundation, Inc.$63,095,441
- Philip J Disaia · University Of California Irvine$41,530,194
- Walter J Curran · Thomas Jefferson University$37,520,030
- Samuel A Wells · Duke University$32,148,803
- Gregory H Reaman · National Childhood Cancer Foundation$19,436,422
Research focus
Neoplasm /Cancer ChemotherapyHuman SubjectNeoplasm /Cancer Relapse /RecurrencePatient Oriented ResearchMonoclonal AntibodyNeoplasm /Cancer RadioimmunotherapyNonhodgkin'S LymphomaHuman Therapy EvaluationRadionuclidesAntitumor AntibodyCd22 MoleculeCombination Cancer TherapyIodineClinical ResearchLymphomaHuman MortalityHuman Old Age (65+)Drug ResistanceData Collection Methodology /EvaluationAgingLongitudinal Human StudyClinical Trial Phase IiBehavior TestBehavioral /Social Science Research Tag
Grant awards (7)
Novel Monoclonal Antibody Therapies for Lymphoma$108,000
K23 · FY2005 · RR
Novel Monoclonal Antibody Therapies for Lymphoma$108,000
K23 · FY2004 · RR
Ph. II trial/ depsipeptide in cutaneous T-cell lymphoma/ relapsed peripheral$45,562
M01 · FY2004 · RR
Evaluation of functional status, quality of life, /outcome /older lymphoma pts$11,192
M01 · FY2004 · RR
Novel Monoclonal Antibody Therapies for Lymphoma$108,000
K23 · FY2003 · RR
Novel Monoclonal Antibody Therapies for Lymphoma$108,000
K23 · FY2002 · RR
Novel Monoclonal Antibody Therapies for Lymphoma$108,000
K23 · FY2001 · RR